Advanced search
1 file | 1.81 MB Add to list

A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs

Author
Organization
Abstract
Conventional treatments of osteoarthritis (OA) reduce pain and the inflammatory response but do not repair the damaged cartilage. Xenogeneic peripheral blood-derived equine chondrogenically induced mesenchymal stem cells (ciMSC) could thus provide an interesting alternative. Six client-owned dogs with confirmed elbow OA were subjected to a baseline orthopedic examination, pressure plate analysis, general clinical examination, hematological analysis, synovial fluid sampling, and radiographic examination, and their owners completed two surveys. After all examinations, a 0.9% saline solution (placebo control product=CP) was administered intra-articularly. After 6 weeks, all examinations were repeated, owners again completed two surveys, and equine ciMSCs were administered in the same joint. After another 6 weeks, dogs were returned for a final follow-up. No serious adverse events or suspected adverse drug reactions were present during this study. No significant differences in blood analysis were noted between the CP and ciMSC treatment. Two adverse events were observed, both in the same dog, one after CP treatment and one after ciMSC treatment. The owner surveys revealed significantly less pain and lameness after ciMSC treatment compared to after CP treatment. There was no significant difference in the orthopedic examination parameters, the radiographic examination, synovial fluid sampling, and pressure plate analysis between CP treatment and ciMSC treatment. A single intra-articular administration of equine ciMSCs proved to be a well-tolerated treatment, which reduced lameness and pain according to the owner's evaluations compared to a placebo treatment.

Downloads

  • Daems et al 2019 Stem Cells International.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.81 MB

Citation

Please use this url to cite or link to this publication:

MLA
Daems, Robert, et al. “A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs.” STEM CELLS INTERNATIONAL, vol. 2019, 2019.
APA
Daems, R., Van Hecke, L., Schwarzkopf, I., Depuydt, E., Broeckx, S. Y., David, M., … Spaas, J. (2019). A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs. STEM CELLS INTERNATIONAL, 2019.
Chicago author-date
Daems, Robert, Lore Van Hecke, Ilona Schwarzkopf, Eva Depuydt, Sarah Y. Broeckx, Michael David, Charlotte Beerts, Peter Vandekerckhove, and Jan Spaas. 2019. “A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs.” STEM CELLS INTERNATIONAL 2019.
Chicago author-date (all authors)
Daems, Robert, Lore Van Hecke, Ilona Schwarzkopf, Eva Depuydt, Sarah Y. Broeckx, Michael David, Charlotte Beerts, Peter Vandekerckhove, and Jan Spaas. 2019. “A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs.” STEM CELLS INTERNATIONAL 2019.
Vancouver
1.
Daems R, Van Hecke L, Schwarzkopf I, Depuydt E, Broeckx SY, David M, et al. A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs. STEM CELLS INTERNATIONAL. 2019;2019.
IEEE
[1]
R. Daems et al., “A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs,” STEM CELLS INTERNATIONAL, vol. 2019, 2019.
@article{8659918,
  abstract     = {Conventional treatments of osteoarthritis (OA) reduce pain and the inflammatory response but do not repair the damaged cartilage. Xenogeneic peripheral blood-derived equine chondrogenically induced mesenchymal stem cells (ciMSC) could thus provide an interesting alternative. Six client-owned dogs with confirmed elbow OA were subjected to a baseline orthopedic examination, pressure plate analysis, general clinical examination, hematological analysis, synovial fluid sampling, and radiographic examination, and their owners completed two surveys. After all examinations, a 0.9% saline solution (placebo control product=CP) was administered intra-articularly. After 6 weeks, all examinations were repeated, owners again completed two surveys, and equine ciMSCs were administered in the same joint. After another 6 weeks, dogs were returned for a final follow-up. No serious adverse events or suspected adverse drug reactions were present during this study. No significant differences in blood analysis were noted between the CP and ciMSC treatment. Two adverse events were observed, both in the same dog, one after CP treatment and one after ciMSC treatment. The owner surveys revealed significantly less pain and lameness after ciMSC treatment compared to after CP treatment. There was no significant difference in the orthopedic examination parameters, the radiographic examination, synovial fluid sampling, and pressure plate analysis between CP treatment and ciMSC treatment. A single intra-articular administration of equine ciMSCs proved to be a well-tolerated treatment, which reduced lameness and pain according to the owner's evaluations compared to a placebo treatment.},
  articleno    = {4587594},
  author       = {Daems, Robert and Van Hecke, Lore and Schwarzkopf, Ilona and Depuydt, Eva and Broeckx, Sarah Y. and David, Michael and Beerts, Charlotte and Vandekerckhove, Peter and Spaas, Jan},
  issn         = {1687-966X},
  journal      = {STEM CELLS INTERNATIONAL},
  language     = {eng},
  pages        = {12},
  title        = {A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs},
  url          = {http://dx.doi.org/10.1155/2019/4587594},
  volume       = {2019},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: